基于溶瘤性水泡性口炎病毒的细胞疫苗通过增强自然杀伤细胞和CD8 T细胞功能改善三阴性乳腺癌的预后。 - Suppr

Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8 T-cell functionality.

作者信息

Niavarani Seyedeh-Raheleh, Lawson Christine, Boudaud Marie, Simard Camille, Tai Lee-Hwa

机构信息

Immunology and Cell Biology, Université de Sherbrooke, Faculté de médecine et des sciences de la santé, Sherbrooke, Quebec, Canada.

Pediatrics, Université de Sherbrooke, Faculté de médecine et des sciences de la santé, Sherbrooke, Quebec, Canada.

出版信息

J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000465.

DOI:10.1136/jitc-2019-000465

PMID:32179632

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7073779/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e45/7073779/8248d94f4974/jitc-2019-000465f01.jpg

相似文献

Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8 T-cell functionality.

J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000465.

Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.

Breast Cancer Res. 2024 May 15;26(1):78. doi: 10.1186/s13058-024-01818-5.

Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.

Int J Cancer. 2019 Oct 1;145(7):1958-1969. doi: 10.1002/ijc.32325. Epub 2019 Apr 29.

Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.

Nat Commun. 2019 Jul 19;10(1):3236. doi: 10.1038/s41467-019-11137-5.

Antifibrotic Therapy Augments the Antitumor Effects of Vesicular Stomatitis Virus Via Reprogramming Tumor Microenvironment.

Hum Gene Ther. 2022 Mar;33(5-6):237-249. doi: 10.1089/hum.2021.048. Epub 2021 Oct 26.

Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.

Cancer Res. 2007 Mar 15;67(6):2840-8. doi: 10.1158/0008-5472.CAN-06-3974.

Delayed contraction of the CD8+ T cell response toward lymphocytic choriomeningitis virus infection in mice lacking serglycin.

J Immunol. 2008 Jul 15;181(2):1043-51. doi: 10.4049/jimmunol.181.2.1043.

Does the vesicular stomatitis virus really have a selective oncolytic effect in human cancer?

Int J Cancer. 2010 May 15;126(10):2509-10. doi: 10.1002/ijc.24922.

Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer.

Cancer Immunol Res. 2020 May;8(5):618-631. doi: 10.1158/2326-6066.CIR-19-0703. Epub 2020 Mar 3.

Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.

Int J Mol Sci. 2020 Sep 1;21(17):6347. doi: 10.3390/ijms21176347.

引用本文的文献

The Immunoproteasome Is Expressed but Dispensable for a Leukemia Infected Cell Vaccine.

Vaccines (Basel). 2025 Aug 5;13(8):835. doi: 10.3390/vaccines13080835.

Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models.

Mol Ther Oncol. 2025 Jun 25;33(3):201016. doi: 10.1016/j.omton.2025.201016. eCollection 2025 Sep 18.

Therapeutic limitations of oncolytic VSVd51-mediated miR-199a-5p delivery in triple negative breast cancer models.

Sci Rep. 2025 May 13;15(1):16634. doi: 10.1038/s41598-025-01584-0.

Enhancing the Efficacy of Breast Cancer Immunotherapy Using a Smac-Armed Oncolytic Virus.

Cancers (Basel). 2024 Sep 24;16(19):3248. doi: 10.3390/cancers16193248.

Shifting cold to hot tumors by nanoparticle-loaded drugs and products.

Clin Transl Oncol. 2025 Jan;27(1):42-69. doi: 10.1007/s12094-024-03577-3. Epub 2024 Jun 26.

The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer.

Front Immunol. 2024 Feb 29;15:1368687. doi: 10.3389/fimmu.2024.1368687. eCollection 2024.

Immune landscape and response to oncolytic virus-based immunotherapy.

Front Med. 2024 Jun;18(3):411-429. doi: 10.1007/s11684-023-1048-0. Epub 2024 Mar 8.

Update on current and new potential immunotherapies in breast cancer, from bench to bedside.

Front Immunol. 2024 Feb 15;15:1287824. doi: 10.3389/fimmu.2024.1287824. eCollection 2024.

Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.

Front Immunol. 2023 Nov 8;14:1286750. doi: 10.3389/fimmu.2023.1286750. eCollection 2023.

Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment.

J Cancer Metastasis Treat. 2023;9. doi: 10.20517/2394-4722.2022.92. Epub 2023 Apr 4.

本文引用的文献

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27.

Recent advances in triple negative breast cancer: the immunotherapy era.

BMC Med. 2019 May 9;17(1):90. doi: 10.1186/s12916-019-1326-5.

Cancer immunoediting and resistance to T cell-based immunotherapy.

Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. doi: 10.1038/s41571-018-0142-8.

T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.

Cancer Immunol Res. 2018 Sep;6(9):990-1000. doi: 10.1158/2326-6066.CIR-18-0277.

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

Cancer Discov. 2018 Sep;8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367. Epub 2018 Aug 16.

The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.

Cancer Treat Rev. 2018 Jun;67:34-44. doi: 10.1016/j.ctrv.2018.04.010. Epub 2018 May 2.

Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer.

J Target Ther Cancer. 2018 Feb;7(1):52-69. Epub 2018 Feb 14.

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Sci Transl Med. 2018 Jan 3;10(422). doi: 10.1126/scitranslmed.aao1641.

Immunogenic and Non-immunogenic Cell Death in the Tumor Microenvironment.

Adv Exp Med Biol. 2017;1036:65-79. doi: 10.1007/978-3-319-67577-0_5.

Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.

Asia Pac J Clin Oncol. 2018 Feb;14(1):32-39. doi: 10.1111/ajco.12748. Epub 2017 Aug 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8 T-cell functionality.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献